Interferon in the treatment of cutaneous T-cell lymphoma

Olsen, Elise A.

doi:10.1111/j.1396-0296.2003.01643.x

Cited by 121 publications

(101 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These studies used high doses of 36 to 50 million IU daily or 3 times weekly (maximum tolerated dose, 18 million IU daily) with objective response rates of 45% and 64% with considerable toxicity. 20 At lower interferon doses, side effects were less severe, although the response rates were also lower. The best interferon dose is not completely established; however, the dose of 3 MU, increased to 5 MU TIW is commonly used.…”

Section: Discussionmentioning

confidence: 99%

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

Straus

Duvic

Kuzel

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T‐cell lymphoma (CTCL). Interferon alfa has also been used for many years as an effective treatment for this disease. The results in recent case reports of the combination of bexarotene and interferon alfa have been promising. Based on more extensive results reported with the combination of other retinoids with interferon alfa, the present study attempted to determine the response rate, response duration, and safety of bexarotene (Targretin capsules, Ligand Pharmaceuticals, San Diego, Calif) alone and then with the addition of interferon alfa‐2b (Intron‐A, Schering‐Plough, Kenilworth, NJ).METHODS.Patients with biopsy‐proven CTCL, TNM stages IB, IIA, IIB‐IV, were treated with oral bexarotene 300 mg/m2/day for at least 8 weeks. If a complete response was not seen after 8 weeks, interferon alfa‐2b 3 million units (MU) subcutaneously was added, and increased to 5 MU if tolerated, 3 times a week.RESULTS.A total of 22 patients were enrolled at 5 sites, and 18 patients were assessable for response. Overall response rate for combined bexarotene and interferon alfa was 39% (95% confidence interval [CI]: 17%–64%), including 1 patient with a clinical complete response, 6 patients with partial response, 3 patients with stable disease, and 8 patients with progressive disease. Three partial responses were first noted during the bexarotene‐alone phase. Adverse events were generally manageable, and only 1 patient was withdrawn from study for hypertriglyceridemia.CONCLUSIONS.The addition of interferon alfa‐2b did not increase the response rate that would have been expected with bexarotene alone. Cancer 2007. © 2007 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

Straus

Duvic

Kuzel

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…Although it is generally unknown whether SzS patients are deficient in IFN-␣ production, most IFN-␣-treated patients experience significant clinical responses. 50 Thus, the ability to restore deficient IFN-␣ production by the exogenous administration of this cytokine represents an important therapeutic advance for these patients.…”

Section: Discussionmentioning

confidence: 99%

Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines

Wysocka

Zaki

French

et al. 2002

Blood

View full text Add to dashboard Cite

“…Responses, which may be achieved within a few months, are observed in patients with tumor-stage MF and SS. Furthermore, interferon-alpha may be successfully combined with a number of other therapeutic modalities, including PUVA, bexarotene, chemotherapy and ECP, which are frequently utilized in the management of these patients [289][290][291][292][293][294][295][296][297][298][299][300][301][302]. For example, in a cohort of 51 patients (42 of which had advancedstage disease) treated with single-agent, low-dose, interferon-alpha, responses were observed in 34 (67%), 21 (41%) of which were complete and maintained long-term in nine patients [288].…”

Section: Interferon-alphamentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Interferon in the treatment of cutaneous T-cell lymphoma

Cited by 121 publications

References 72 publications

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Contact Info

Product

Resources

About